By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:



Acadia  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.


Company News
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017 7:05:58 AM
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017 7:10:48 AM
Sunovion Enters Into License Agreement For Three Approved Treatment Options For People With COPD In The U.S. 12/21/2016 12:41:47 PM
Sunovion Announces Collaboration With AMDA – The Society For Post-Acute And Long-Term Care Medicine 12/15/2016 8:14:26 AM
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis 12/2/2016 7:44:28 AM
Demi Lovato, Sunovion And Leading Advocacy Organizations Launch The Be Vocal Collection In Partnership With Getty Images To Encourage The Realistic Portrayal Of Mental Health 11/30/2016 10:20:26 AM
Sunovion Recognizes Epilepsy And COPD Awareness Months In The U.S. During November 11/1/2016 12:30:16 PM
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia 10/27/2016 11:29:40 AM
Sunovion Completes Acquisition Of Cynapsus (CYNA) 10/21/2016 8:25:35 AM
The American College of Chest Physicians And Sunovion Announce Strategic Initiative Focused On The Importance Of Drug Delivery In The Management Of COPD 10/20/2016 3:01:32 PM